C. Chighizola, Y. Shoenfeld, and P. L. Meroni, Systemic sclerosis. Introduction, Autoimmun Rev, vol.10, pp.239-279, 2011.

E. C. Leroy and T. A. Medsger, Criteria for the classification of early systemic sclerosis, J Rheumatol, vol.28, pp.1573-1579, 2001.

A. C. Desbois and P. Cacoub, Systemic sclerosis: an update in 2016, Autoimmun Rev, vol.15, pp.417-443, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01297570

M. Elhai, C. Meune, M. Boubaya, J. Avouac, E. Hachulla et al., Mapping and predicting mortality from systemic sclerosis, Ann Rheum Dis, vol.76, pp.1897-905, 2017.

D. R. Poudel, D. Jayakumar, A. Danve, S. T. Sehra, and C. T. Derk, Determinants of mortality in systemic sclerosis: a focused review, Rheumatol Int, vol.38, pp.1847-58, 2017.

N. Zeineddine, L. E. Khoury, and J. Mosak, Systemic sclerosis and malignancy: a review of current data, J Clin Med Res, vol.8, pp.625-657, 2016.

B. Granel, A. Daumas, E. Jouve, J. R. Harle, P. S. Nguyen et al., Safety, tolerability and potential efficacy of injection of autologous adiposederived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial, Ann Rheum Dis, vol.74, pp.2175-82, 2015.

A. J. Friedenstein, J. F. Gorskaja, and N. N. Kulagina, Fibroblast precursors in normal and irradiated mouse hematopoietic organs, Exp Hematol, vol.4, pp.267-74, 1976.

L. Da-silva-meirelles, P. C. Chagastelles, and N. B. Nardi, Mesenchymal stem cells reside in virtually all post-natal organs and tissues, J Cell Sci, vol.119, pp.2204-2217, 2006.

N. Guimaraes-camboa, P. Cattaneo, Y. Sun, T. Moore-morris, Y. Gu et al., Pericytes of multiple organs do not behave as mesenchymal stem cells in vivo, Cell Stem Cell, vol.20, pp.345-59, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01785316

M. Dominici, L. Blanc, K. Mueller, I. Slaper-cortenbach, I. Marini et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement, Cytotherapy, vol.8, pp.315-322, 2006.

M. Maumus, C. Jorgensen, and D. Noel, Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes, Biochimie, vol.95, pp.2229-2263, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00832507

P. Luz-crawford, D. Noel, X. Fernandez, M. Khoury, F. Figueroa et al., Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway, PLoS ONE, vol.7, p.45272, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00758222

Z. Abbasi-malati, A. M. Roushandeh, Y. Kuwahara, and M. H. Roudkenar, Mesenchymal stem cells on horizon: a new arsenal of therapeutic agents, Stem Cell Rev, vol.14, pp.484-99, 2018.

S. Kern, H. Eichler, J. Stoeve, H. Kluter, and K. Bieback, Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue, Stem Cells, vol.24, pp.1294-301, 2006.

K. A. Keyser, K. E. Beagles, and H. P. Kiem, Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation, Cell Transplant, vol.16, pp.555-62, 2007.

M. Ruiz, S. Cosenza, M. Maumus, C. Jorgensen, and D. Noel, Therapeutic application of mesenchymal stem cells in osteoarthritis, Expert Opin Biol Ther, vol.16, pp.33-42, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01834251

A. Toyoshima, T. Yasuhara, and I. Date, mesenchymal stem cell therapy for ischemic stroke, Acta Med Okayama, vol.71, pp.263-271, 2017.

A. Cras, D. Farge, T. Carmoi, J. J. Lataillade, D. D. Wang et al., Update on mesenchymal stem cell-based therapy in lupus and scleroderma, Arthritis Res Ther, vol.17, p.301, 2015.

H. Yu, K. Lu, J. Zhu, and J. Wang, Stem cell therapy for ischemic heart diseases, Br Med Bull, vol.121, pp.135-54, 2017.

F. Paduano, M. Marrelli, M. Amantea, C. Rengo, S. Rengo et al., Adipose tissue as a strategic source of mesenchymal stem cells in bone regeneration: a topical review on the most promising craniomaxillofacial applications, Int J Mol Sci, vol.18, p.2140, 2017.

M. M. Lalu, L. Mcintyre, C. Pugliese, D. Fergusson, B. W. Winston et al., Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials, PLoS ONE, vol.7, p.47559, 2012.

C. M. Artlett, Animal models of systemic sclerosis: their utility and limitations, Open Access Rheumatol, vol.6, pp.65-81, 2014.

A. Moeller, K. Ask, D. Warburton, J. Gauldie, and M. Kolb, The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?, Int J Biochem Cell Biol, vol.40, pp.362-82, 2008.

L. A. Ortiz, F. Gambelli, C. Mcbride, D. Gaupp, M. Baddoo et al., Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects, Proc Natl Acad Sci, vol.100, pp.8407-8418, 2003.

M. Rojas, J. Xu, C. R. Woods, A. L. Mora, W. Spears et al., Bone marrowderived mesenchymal stem cells in repair of the injured lung, Am J Respir Cell Mol Biol, vol.33, pp.145-52, 2005.

M. Kumamoto, T. Nishiwaki, N. Matsuo, H. Kimura, and K. Matsushima, Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury, Eur Respir J, vol.34, pp.740-748, 2009.

F. Zhao, Y. F. Zhang, Y. G. Liu, J. J. Zhou, Z. K. Li et al., Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats, Transplant Proc, vol.40, pp.1700-1705, 2008.

S. H. Lee, A. S. Jang, Y. E. Kim, J. Y. Cha, T. H. Kim et al., Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis, Respir Res, vol.11, p.16, 2010.

Y. Wu, S. Huang, J. Enhe, K. Ma, S. Yang et al., Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice, Int Wound J, vol.11, pp.701-711, 2014.

Y. Moodley, D. Atienza, U. Manuelpillai, C. S. Samuel, J. Tchongue et al., Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury, Am J Pathol, vol.175, pp.303-316, 2009.

A. Cargnoni, L. Gibelli, A. Tosini, P. B. Signoroni, C. Nassuato et al., Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis, Cell Transplant, vol.18, pp.405-427, 2009.

O. Garcia, G. Carraro, G. Turcatel, M. Hall, S. Sedrakyan et al., Amniotic fluid stem cells inhibit the progression of bleomycin-induced pulmonary fibrosis via CCL2 modulation in bronchoalveolar lavage, PLoS ONE, vol.8, 2013.

Y. Moodley, V. Vaghjiani, J. Chan, S. Baltic, M. Ryan et al., Antiinflammatory effects of adult stem cells in sustained lung injury: a comparative study, PLoS ONE, vol.8, p.69299, 2013.

S. H. Lee, E. J. Lee, S. Y. Lee, J. H. Kim, J. J. Shim et al., The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice, Exp Lung Res, vol.40, pp.117-142, 2014.

M. M. Sabry, S. A. Elkalawy, R. K. Abo-elnour, and A. Df, Histolgical and immunohistochemical study on the effect of stem cell therapy on bleomycin induced pulmonary fibrosis in albino rat, Int J Stem Cells, vol.7, pp.33-42, 2014.

R. K. Braun, J. M. Koch, T. A. Hacker, D. Pegelow, J. Kim et al., Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion, Cytotherapy, vol.18, pp.536-581, 2016.

M. Uji, A. Nakada, T. Nakamura, and K. Hirata, Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model, Osaka City Med J, vol.61, pp.81-91, 2015.

S. H. Yu, L. J. Liu, B. Lv, C. L. Che, D. P. Fan et al., Inhibition of bleomycininduced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF-gamma, and TGF-beta, Cell Biochem Funct, vol.33, pp.356-66, 2015.

J. Tashiro, S. J. Elliot, D. J. Gerth, X. Xia, S. Pereira-simon et al., Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis, Transl Res, vol.166, pp.554-67, 2015.

G. A. Rubio, S. J. Elliot, T. C. Wikramanayake, X. Xia, S. Pereira-simon et al., Mesenchymal stromal cells prevent bleomycin-induced lung and skin fibrosis in aged mice and restore wound healing, J Cell Physiol, vol.233, pp.5503-5515, 2018.

A. Servettaz, C. Goulvestre, N. Kavian, C. Nicco, P. Guilpain et al., Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse, J Immunol, vol.182, pp.5855-64, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00517814

A. T. Maria, K. Toupet, C. Bony, N. Pirot, M. C. Vozenin et al., Anti-fibrotic, anti-oxidant and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis, Arthritis Rheumatol, vol.68, pp.1013-1038, 2016.

A. T. Maria, K. Toupet, M. Maumus, G. Fonteneau, L. Quellec et al., Human adipose mesenchymal stem cells as potent antifibrosis therapy for systemic sclerosis, J Autoimmun, vol.70, pp.31-40, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01834289

A. T. Maria, C. Jorgensen, L. Quellec, A. Noel, D. et al., Arthritis Rheumatol, vol.68, pp.2348-50, 2016.

R. M. Baxter, T. P. Crowell, M. E. Mccrann, E. M. Frew, and H. Gardner, Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents, Lab Invest, vol.85, pp.1199-209, 2005.

C. Chen, D. Wang, A. Moshaverinia, D. Liu, X. Kou et al., Mesenchymal stem cell transplantation in tight-skin mice identifies miR-151-5p as a therapeutic target for systemic sclerosis, Cell Res, vol.27, pp.559-77, 2017.

K. Huang, X. Kang, X. Wang, S. Wu, X. J. Li et al., Conversion of bone marrow mesenchymal stem cells into type II alveolar epithelial cells reduces pulmonary fibrosis by decreasing oxidative stress in rats, Mol Med Rep, vol.11, pp.1685-92, 2015.

Q. Shen, B. Chen, Z. Xiao, L. Zhao, X. Xu et al., Paracrine factors from mesenchymal stem cells attenuate epithelial injury and lung fibrosis, Mol Med Rep, vol.11, pp.2831-2838, 2015.

L. A. Ortiz, M. Dutreil, C. Fattman, A. C. Pandey, G. Torres et al., Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury, Proc Natl Acad Sci, vol.104, pp.11002-11009, 2007.

E. F. Cahill, H. Kennelly, F. Carty, B. P. Mahon, and K. English, Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycininduced pulmonary fibrosis, Stem Cells Transl Med, vol.5, pp.1307-1325, 2016.

Y. W. Lan, S. M. Theng, T. T. Huang, K. B. Choo, C. M. Chen et al., Oncostatin M-preconditioned mesenchymal stem cells alleviate bleomycin-induced pulmonary fibrosis through paracrine effects of the hepatocyte growth factor, Stem Cells Transl Med, vol.6, pp.1006-1023, 2017.

Y. W. Lan, K. B. Choo, C. M. Chen, T. H. Hung, Y. B. Chen et al., Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis, Stem Cell Res Ther, vol.6, p.97, 2015.

Q. Wang, H. Zhu, W. G. Zhou, X. C. Guo, M. J. Wu et al., N-acetylcysteinepretreated human embryonic mesenchymal stem cell administration protects against bleomycin-induced lung injury, Am J Med Sci, vol.346, pp.113-135, 2013.

L. Huleihel, J. Sellares, N. Cardenes, D. Alvarez, R. Faner et al., Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model, Am J Physiol Lung Cell Mol Physiol, vol.313, pp.92-103, 2017.

F. Min, F. Gao, Q. Li, and Z. Liu, Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury, Mol Med Rep, vol.11, pp.2387-96, 2015.

M. Jiang, Y. Yu, J. Luo, Q. Gao, L. Zhang et al., Bone Marrow-derived mesenchymal stem cells expressing thioredoxin 1 attenuate bleomycininduced skin fibrosis and oxidative stress in scleroderma, J Invest Dermatol, vol.137, pp.1223-1256, 2017.

M. F. Pittenger, A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas et al., Multilineage potential of adult human mesenchymal stem cells, Science, vol.284, pp.143-150, 1999.

A. T. Maria, M. Maumus, L. Quellec, A. Jorgensen, C. Noel et al., Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis, Clin Rev Allergy Immunol, vol.52, pp.234-59, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01342436

J. Peltzer, M. Aletti, N. Frescaline, E. Busson, J. J. Lataillade et al., Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges, Front Immunol, vol.9, 2013.

C. Bocelli-tyndall, L. Bracci, G. Spagnoli, A. Braccini, M. Bouchenaki et al., Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous-and allogeneic-stimulated lymphocytes in vitro, Rheumatology, vol.46, pp.403-411, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00479753

J. Larghero, D. Farge, A. Braccini, S. Lecourt, A. Scherberich et al., Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis, Ann Rheum Dis, vol.67, pp.443-452, 2008.

N. Scuderi, S. Ceccarelli, M. G. Onesti, P. Fioramonti, C. Guidi et al., Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis, Cell Transplant, vol.22, pp.779-95, 2013.

C. Capelli, E. Zaccara, P. Cipriani, D. Benedetto, P. Maglione et al., Phenotypical and functional characteristics of "in vitro" expanded adipose-derived mesenchymal stromal cells from patients with systemic sclerosis, Cell Transplant, vol.26, pp.841-54, 2017.

M. Orciani, S. Svegliati, S. Gorbi, T. Spadoni, R. Lazzarini et al., Alterations of ROS pathways in scleroderma begin at stem cell level, J Biol Regul Homeost Agents, vol.27, pp.211-235, 2013.

G. Fonteneau, C. Bony, R. Goulabchand, A. Maria, L. Quellec et al., Serum-mediated oxidative stress from systemic sclerosis patients affects mesenchymal stem cell function. Front Immunol, vol.8, p.988, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01623926

V. Vanneaux, D. Farge-bancel, S. Lecourt, J. Baraut, A. Cras et al., Expression of transforming growth factor beta receptor II in mesenchymal stem cells from systemic sclerosis patients, BMJ Open, vol.3, 2013.

D. Papa, N. Quirici, N. Soligo, D. Scavullo, C. Cortiana et al., Bone marrow endothelial progenitors are defective in systemic sclerosis, Arthritis Rheum, vol.54, pp.2605-2620, 2006.

P. Cipriani, A. Marrelli, P. D. Benedetto, V. Liakouli, F. Carubbi et al., Scleroderma mesenchymal stem cells display a different phenotype from healthy controls; implications for regenerative medicine, Angiogenesis, vol.16, pp.595-607, 2013.

P. Cipriani, D. Benedetto, P. Liakouli, V. , D. Papa et al., Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy, Clin Exp Immunol, vol.173, pp.195-206, 2013.

P. Cipriani, D. Benedetto, P. Ruscitti, P. Campese, A. F. Liakouli et al., Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features, Arthritis Res Ther, vol.16, p.442, 2014.

B. Hegner, T. Schaub, R. Catar, A. Kusch, P. Wagner et al., Intrinsic deregulation of vascular smooth muscle and myofibroblast differentiation in mesenchymal stromal cells from patients with systemic sclerosis, PLoS ONE, vol.11, 2016.

S. Guiducci, M. Manetti, E. Romano, B. Mazzanti, C. Ceccarelli et al., Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro, Ann Rheum Dis, vol.70, pp.2011-2032, 2011.

M. Griffin, C. M. Ryan, O. Pathan, D. Abraham, C. P. Denton et al., Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine, Stem Cell Res Ther, vol.8, p.23, 2017.

J. Bank, S. M. Fuller, G. I. Henry, and L. S. Zachary, Fat grafting to the hand in patients with Raynaud phenomenon: a novel therapeutic modality, Plast Reconstr Surg, vol.133, pp.1109-1127, 2014.

D. Papa, N. , D. Luca, G. Sambataro, D. Zaccara et al., Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis, Cell Transplant, vol.24, pp.2297-305, 2015.

F. Virzi, P. Bianca, A. Giammona, T. Apuzzo, D. Franco et al., Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients, Stem Cell Res Ther, vol.8, p.236, 2017.

M. Schendel, M. Foll, J. Muller, L. P. Keysser, G. Behre et al., Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L, Leukemia, vol.22, pp.1062-1066, 2008.

G. Keyszer, M. Christopeit, S. Fick, M. Schendel, B. M. Taute et al., Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases, Arthritis Rheum, vol.63, pp.2540-2542, 2011.

M. G. Onesti, P. Fioramonti, S. Carella, P. Fino, C. Marchese et al., Improvement of mouth functional disability in systemic sclerosis patients over one year in a trial of fat transplantation versus adipose-derived stromal cells, Stem Cells Int, p.2416192, 2016.

P. Guillaume-jugnot, A. Daumas, J. Magalon, N. Sautereau, J. Veran et al., State of the art. Autologous fat graft and adipose tissue-derived stromal vascular fraction injection for hand therapy in systemic sclerosis patients, Curr Res Transl Med, vol.64, pp.35-42, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01460050

A. Daumas, J. Magalon, E. Jouve, R. Truillet, D. Casanova et al., A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol, Curr Res Transl Med, vol.65, p.20479, 2017.